Literature DB >> 12884171

Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa.

Eli Schwartz1, Shay Bujanover, Kevin C Kain.   

Abstract

We report a case of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to Kenya. Recurrent parasitemia occurred 30 days after directly observed therapy with a combination of atovaquone and proguanil. Treatment failure was confirmed by genetic fingerprinting and sequencing. The primary isolate had wild-type sequence of cytochrome b; however, the recrudescent isolate had a single mutation at position 268 (Tyr268Ser).

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12884171     DOI： 10.1086/375599

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  31 in total

1.  First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.

Authors:  Helene Savini; Hervé Bogreau; Lionel Bertaux; Housem Bouchiba; Philippe Kraemer; Daniel Parzy; Eric Garnotel; Christophe Rogier; Fabrice Simon; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

2.  Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.

Authors:  Luicer A Ingasia; Hoseah M Akala; Mabel O Imbuga; Benjamin H Opot; Fredrick L Eyase; Jacob D Johnson; Wallace D Bulimo; Edwin Kamau
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

3.  Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reports.

Authors:  Gilles Cottrell; Lise Musset; Véronique Hubert; Jacques Le Bras; Jérôme Clain
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor.

Authors:  Jennifer L Guler; John White; Margaret A Phillips; Pradipsinh K Rathod
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

5.  Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated Plasmodium falciparum malaria in travelers.

Authors:  Shirly Grynberg; Tamar Lachish; Eran Kopel; Eyal Meltzer; Eli Schwartz
Journal:  Am J Trop Med Hyg       Date:  2014-11-04       Impact factor: 2.345

6.  HDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 complex.

Authors:  Cindy Vallières; Nicholas Fisher; Thomas Antoine; Mohammed Al-Helal; Paul Stocks; Neil G Berry; Alexandre S Lawrenson; Stephen A Ward; Paul M O'Neill; Giancarlo A Biagini; Brigitte Meunier
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

7.  Saccharomyces cerevisiae-based mutational analysis of the bc1 complex Qo site residue 279 to study the trade-off between atovaquone resistance and function.

Authors:  Zehua Song; Jérôme Clain; Bogdan I Iorga; Zhou Yi; Nicholas Fisher; Brigitte Meunier
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

8.  Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.

Authors:  Ana Afonso; Zoraima Neto; Helena Castro; Dinora Lopes; Ana C Alves; Ana M Tomás; Virgílio D Rosário
Journal:  Malar J       Date:  2010-05-21       Impact factor: 2.979

9.  Advanced Molecular Detection of Malarone Resistance.

Authors:  Eldin Talundzic; Mateusz M Plucinski; Shweta Biliya; Luciana M Silva-Flannery; Paul M Arguin; Eric S Halsey; John W Barnwell; Fredrik Vannberg; Venkatachalam Udhayakumar
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Severe atovaquone-resistant Plasmodium falciparum malaria in a Canadian traveller returned from the Indian subcontinent.

Authors:  Thomas L Perry; Prativa Pandey; Jennifer M Grant; Kevin C Kain
Journal:  Open Med       Date:  2009-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.